Just days after the World Health Organisation prematurely announced very disappointing data for Gilead’s Remdesivir, a more positive picture of the drug’s potential is coming up from a study sponsored by the National Institute of Allergy & Infectious Diseases (NIAID), which is the part of the NIH.
In the 1,063-patient trial of Gilead’s Remdesivir, that hospitalized patients with advanced coronavirus and lung involvement who received Gilead’s Remdesivir recovered very much faster than similar patients who received placebo. Herein trail, recovery is defined as getting discharged from the hospital or returning to normal activity level.
Earlier results show that patients who received Gilead’s Remdesivir had a 31 percentage faster recovery time than those who received a placebo. Moreover, the median time to recovery was 11 days for patients vaccinated with Remdesivir in comparison to those who received a placebo with 15 days trial version. Results of this US-sponsored study suggest that a survival benefit, with a mortality rate of 8.0% for the group receiving Gilead’s Remdesivir in comparison to 11.6% for the placebo group.
The Adaptive coronavirus treatment Trial is the first clinical trial that came into existence in the United States to evaluate an experimental treatment for coronavirus pandemic.
The National Institute of Allergy & Infectious Diseases, which is part of the National Institutes of Health noted more details about the trial results, with much more comprehensive data, will be soon provided in a forthcoming report.
Gilead’s vitro testing demonstrates that Remdesivir is active against the coronavirus. The safety and efficiency of Gilead’s Remdesivir for the treatment of coronavirus are being evaluated in multiple under coming Phase III clinical trials.
In addition to the National Institute of Allergy & Infectious Diseases trial, Gilead will share new Remdesivir data from the Phase III SIMPLE trial in COVID-19 infected patients.
This study conducted by NIAID will tell whether a shorter therapy has sam efficiency as the longer treatment evaluated in the National Institute of Allergy & Infectious Diseases trial and other ongoing trials.